RenovoRx Secures $10 Million in Oversubscribed Private Placement to Fund Growth and Milestones

RenovoRx, a life sciences company, announced the closing of an oversubscribed $10 million private placement led by institutional investors and members of the company's senior management and Board of Directors. The financing will support the acceleration of market adoption and clinical development, including the completion of enrollment in the pivotal Phase III trial and potential Phase III data readout. The company expects to achieve several significant milestones across 2026 and 2027, driving growth in commercial revenues and reducing cash burn.